Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02477696




Registration number
NCT02477696
Ethics application status
Date submitted
12/06/2015
Date registered
23/06/2015

Titles & IDs
Public title
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Scientific title
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Secondary ID [1] 0 0
2014-005530-64
Secondary ID [2] 0 0
ACE-CL-006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Acalabrutinib
Treatment: Drugs - Ibrutinib

Experimental: Acalabrutinib - Participants will receive oral acalabrutinib 100 mg twice daily (BID) until disease progression (PD), or unacceptable toxicity, or other reasons for discontinuation, whichever occurs first.

Active comparator: Ibrutinib - Participants will receive oral ibrutinib 420 mg once daily (QD) until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurrs first.


Treatment: Drugs: Acalabrutinib
Participants will receive oral acalabrutinib as stated in arm description.

Treatment: Drugs: Ibrutinib
Participants will receive oral ibrutinib as stated in arm description.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment
Timepoint [1] 0 0
Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)
Secondary outcome [1] 0 0
Number of Participants With Treatment-emergent Infections Grade >= 3
Timepoint [1] 0 0
Day 1 through 83.5 months (maximum observed duration)
Secondary outcome [2] 0 0
Number of Participants With Treatment-emergent Richter's Transformation
Timepoint [2] 0 0
Day 1 through 83.5 months (maximum observed duration)
Secondary outcome [3] 0 0
Number of Participants With Treatment-emergent Atrial Fibrillation
Timepoint [3] 0 0
Day 1 through 83.5 months (maximum observed duration)
Secondary outcome [4] 0 0
Overall Survival (OS)
Timepoint [4] 0 0
Baseline (Days -28 to -1) through 83.7 months (maximum observed duration)
Secondary outcome [5] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Timepoint [5] 0 0
Day 1 through 83.5 months (maximum observed duration)
Secondary outcome [6] 0 0
Number of Participants With Treatment-emergent Laboratory Abnormalities
Timepoint [6] 0 0
Day 1 through 83.5 months (maximum observed duration)
Secondary outcome [7] 0 0
Number of Participants With Abnormal Vital Signs Reported as TEAEs
Timepoint [7] 0 0
Day 1 through 83.5 months (maximum observed duration)
Secondary outcome [8] 0 0
Percentage of Participants With Lymphocytosis
Timepoint [8] 0 0
Day 1 through 83.5 months (maximum observed duration)
Secondary outcome [9] 0 0
Number of Participants With Electrocardiogram (ECG) Abnormality at Baseline
Timepoint [9] 0 0
Baseline (Days -28 to -1)
Secondary outcome [10] 0 0
Number of Participants With Shift From Baseline to Worst (Grade 3 and 4) Postbaseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
Timepoint [10] 0 0
Baseline (Days -28 to -1) through 83.5 months (maximum observed duration)

Eligibility
Key inclusion criteria
* Men and women = 18 years of age.
* ECOG performance status of 0 to 2.
* Diagnosis of CLL.
* Must have = 1 of the following high-risk prognostic factors:

* Presence of 17p del by central laboratory.
* Presence of 11q del by central laboratory.
* Active disease meeting = 1 of the following IWCLL 2008 criteria for requiring treatment
* Must have received = 1 prior therapies for CLL.
* Meet the following laboratory parameters:

* Absolute neutrophil count (ANC) = 750 cells/µL or = 500 cells/µL in participants with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
* Platelet count = 30,000 cells/µL without transfusion support 7 days before assessment. Participants with transfusion-dependent thrombocytopenia are excluded.
* Serum aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) = 3.0 x upper limit of normal (ULN).
* Total bilirubin = 1.5 x ULN.
* Estimated creatinine clearance = 30 mL/min.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Known CNS lymphoma or leukemia.
* Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
* Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
* Prior exposure to ibrutinib or to a B-cell receptor (BCR) inhibitor or a B-cell lymphoma-2 (BCL-2) inhibitor.
* Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.
* Prior radio- or toxin-conjugated antibody therapy.
* Prior allogeneic stem cell or autologous transplant.
* Major surgery within 4 weeks before first dose of study drug.
* Prior malignancy, except for adequately treated lentigo maligna melanoma, non-melanomatous skin cancer, in situ cervical carcinoma or other malignancy treated with no evidence of active disease > 3 years before Screening and at low risk for recurrence.
* Significant cardiovascular disease within 6 months of screening.
* Known history of infection with human immunodeficiency virus (HIV).
* History of stroke or intracranial hemorrhage within 6 months before randomization.
* History of bleeding diathesis.
* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 7 days of first dose of study drug.
* Requires treatment with a strong cytochrome P450 3A (CYP3A) inhibitor/inducer.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/07/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
3/01/2028
Actual
Sample size
Target
Accrual to date
Final
533
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Darlinghurst
Recruitment hospital [2] 0 0
Research Site - Frankston
Recruitment hospital [3] 0 0
Research Site - Melbourne
Recruitment hospital [4] 0 0
Research Site - St Leonards
Recruitment hospital [5] 0 0
Research Site - Waratah NSW
Recruitment hospital [6] 0 0
Research Site - Wollongong
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
3199 - Frankston
Recruitment postcode(s) [3] 0 0
3000 - Melbourne
Recruitment postcode(s) [4] 0 0
2065 - St Leonards
Recruitment postcode(s) [5] 0 0
2298 - Waratah NSW
Recruitment postcode(s) [6] 0 0
2500 - Wollongong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Montana
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Belgium
State/province [18] 0 0
Brugge
Country [19] 0 0
Belgium
State/province [19] 0 0
Bruxelles
Country [20] 0 0
Belgium
State/province [20] 0 0
Ghent
Country [21] 0 0
Belgium
State/province [21] 0 0
Leuven
Country [22] 0 0
Belgium
State/province [22] 0 0
Yvoir
Country [23] 0 0
Denmark
State/province [23] 0 0
Aalborg
Country [24] 0 0
Denmark
State/province [24] 0 0
Indgang 27B
Country [25] 0 0
France
State/province [25] 0 0
Bobigny
Country [26] 0 0
France
State/province [26] 0 0
Creteil
Country [27] 0 0
France
State/province [27] 0 0
Pierre-Benite
Country [28] 0 0
France
State/province [28] 0 0
Rennes Cedex
Country [29] 0 0
France
State/province [29] 0 0
Rouen
Country [30] 0 0
France
State/province [30] 0 0
Toulouse Cedex
Country [31] 0 0
Germany
State/province [31] 0 0
München
Country [32] 0 0
Germany
State/province [32] 0 0
Ulm
Country [33] 0 0
Hungary
State/province [33] 0 0
Budapest
Country [34] 0 0
Hungary
State/province [34] 0 0
Debrecen
Country [35] 0 0
Hungary
State/province [35] 0 0
Kaposvár
Country [36] 0 0
Israel
State/province [36] 0 0
Haifa
Country [37] 0 0
Israel
State/province [37] 0 0
Jerusalem
Country [38] 0 0
Israel
State/province [38] 0 0
Nahariya
Country [39] 0 0
Israel
State/province [39] 0 0
Petah Tikvah
Country [40] 0 0
Israel
State/province [40] 0 0
Tel Hashomer
Country [41] 0 0
Israel
State/province [41] 0 0
Tiberias
Country [42] 0 0
Italy
State/province [42] 0 0
Bologna
Country [43] 0 0
Italy
State/province [43] 0 0
Cagliari
Country [44] 0 0
Italy
State/province [44] 0 0
Cona
Country [45] 0 0
Italy
State/province [45] 0 0
Firenze
Country [46] 0 0
Italy
State/province [46] 0 0
Meldola
Country [47] 0 0
Italy
State/province [47] 0 0
Milano
Country [48] 0 0
Italy
State/province [48] 0 0
Milan
Country [49] 0 0
Italy
State/province [49] 0 0
Modena
Country [50] 0 0
Italy
State/province [50] 0 0
Ravenna
Country [51] 0 0
Italy
State/province [51] 0 0
Rome
Country [52] 0 0
Netherlands
State/province [52] 0 0
Almere
Country [53] 0 0
Netherlands
State/province [53] 0 0
Amsterdam
Country [54] 0 0
Netherlands
State/province [54] 0 0
Blaricum
Country [55] 0 0
Netherlands
State/province [55] 0 0
Breda
Country [56] 0 0
Netherlands
State/province [56] 0 0
Delft
Country [57] 0 0
Netherlands
State/province [57] 0 0
Dordrecht
Country [58] 0 0
Netherlands
State/province [58] 0 0
Geleen
Country [59] 0 0
Netherlands
State/province [59] 0 0
Groningen
Country [60] 0 0
Netherlands
State/province [60] 0 0
Haarlem
Country [61] 0 0
Netherlands
State/province [61] 0 0
Leiden
Country [62] 0 0
Netherlands
State/province [62] 0 0
Rotterdam
Country [63] 0 0
Netherlands
State/province [63] 0 0
Utrecht
Country [64] 0 0
Netherlands
State/province [64] 0 0
Zutphens
Country [65] 0 0
New Zealand
State/province [65] 0 0
Addington
Country [66] 0 0
New Zealand
State/province [66] 0 0
Auckland
Country [67] 0 0
New Zealand
State/province [67] 0 0
Tauranga
Country [68] 0 0
Poland
State/province [68] 0 0
Bydgoszcz
Country [69] 0 0
Poland
State/province [69] 0 0
Gdansk
Country [70] 0 0
Poland
State/province [70] 0 0
Gdynia
Country [71] 0 0
Poland
State/province [71] 0 0
Kraków
Country [72] 0 0
Poland
State/province [72] 0 0
Lodz
Country [73] 0 0
Poland
State/province [73] 0 0
Olsztyn
Country [74] 0 0
Poland
State/province [74] 0 0
Opole
Country [75] 0 0
Poland
State/province [75] 0 0
Slupsk
Country [76] 0 0
Poland
State/province [76] 0 0
Wroclaw
Country [77] 0 0
Spain
State/province [77] 0 0
Barcelona
Country [78] 0 0
Spain
State/province [78] 0 0
Madrid
Country [79] 0 0
Spain
State/province [79] 0 0
Majadahonda
Country [80] 0 0
Spain
State/province [80] 0 0
Murcia
Country [81] 0 0
Spain
State/province [81] 0 0
Santander
Country [82] 0 0
Turkey
State/province [82] 0 0
Ankara
Country [83] 0 0
Turkey
State/province [83] 0 0
Instabul
Country [84] 0 0
Turkey
State/province [84] 0 0
Istanbul
Country [85] 0 0
Turkey
State/province [85] 0 0
Izmir
Country [86] 0 0
Turkey
State/province [86] 0 0
Kayseri
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Birmingham
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Bournemouth
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Cambridge
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Cardiff
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Greater London
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Hull
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Leeds
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Leicester
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Liverpool
Country [96] 0 0
United Kingdom
State/province [96] 0 0
London
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Manchester
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Nottingham
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Plymouth
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Southampton
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Acerta Pharma BV
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Acerta Clinical Trials
Address 0 0
1-888-292-9613
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP)
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Available to whom?
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://astrazenecagroup-dt.pharmacm.com/DT/Home


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT02477696